oxa-2-cyclohexene-2-carbaldehyde | 26271-66-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧杂环化合物
• 英文名称: oxa-2-cyclohexene-2-carbaldehyde
• 英文别名: 3,4-dihydro-2H-pyran-6-carbaldehyde；5,6-dihydro-4H-pyran-2-carbaldehyde；6-formyl-2,3-dihydropyran
• CAS: 26271-66-9
• 化学式: C₆H₈O₂
• 分子量: 112.128
• InChiKey: RKJLPAOQFUSDCQ-UHFFFAOYSA-N

物化性质

• 沸点：
  82-84 °C(Press: 5 Torr)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  8
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  oxa-2-cyclohexene-2-carbaldehyde 在 sodium borohydrid 作用下， 以 异丙醇 为溶剂， 生成 (3,4-二氢-2H-吡喃-6-基)甲醇
  参考文献：
  名称：

  Dihydropyran derivatives and crop protection agents containing them

  摘要：

  农作物保护剂包含有以下化学式的二氢吡喃：其中变量取代基在规范中有定义。

  公开号：

  US05536734A1
• 作为产物：
  描述：

  5,6-二氢-4H-吡喃-2-甲腈 在 二异丁基氢化铝 作用下， 以 甲苯 为溶剂， 生成 oxa-2-cyclohexene-2-carbaldehyde
  参考文献：
  名称：

  Dihydropyran derivatives and crop protection agents containing them

  摘要：

  农作物保护剂包含有以下化学式的二氢吡喃：其中变量取代基在规范中有定义。

  公开号：

  US05536734A1
• 作为试剂：
  描述：

  sodium;hydride 、 苯酚 、 2,3-dihydropyran-6-ylmethyl methanesulfonate 在 水 、 乙醚 、 magnesium sulfate 、 oxa-2-cyclohexene-2-carbaldehyde 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 4.5h， 以27 g (0.14 mol=57%, based on 6-formyl-2,3-dihydropyran) of the title compound are obtained as a pale yellow oil的产率得到6-Phenoxymethyl-2,3-dihydropyran
  参考文献：
  名称：

  Dihydropyran derivatives and crop protection agents containing them

  摘要：

  农作物保护剂包含公式为##STR1##的二氢吡喃，其中变量取代基在说明书中定义。

  公开号：

  US05536734A1

文献信息

• Amino-triazolopyridine derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06355653B1

  公开（公告）日：2002-03-12

  The invention relates to compounds of formula wherein R1 is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, —(CH2)nOH, halogen or lower alkoxy, and wherein the heteroaryl groups may be optionally linked to the pyrazole ring via an alkylene or alkenyl group, or is phenyl, optionally substituted by one or two substituents being lower alkyl, hydroxy-lower alkyl, halogen, hydroxy or lower alkoxy or is —O(CH2)n,phenyl, benzofuryl, indolyl or benzothiophenyl, or is —S-lower alkyl; R2 and R4 are independently from each other hydrogen, cyano or —S(O)2-phenyl; R3 is hydrogen, halogen or is a 5 or 6 membered heteroaryl group, containing 1 to 3 heteroatoms, selected from N, O or S, and which groups are optionally substituted by one or two substituents, which are lower alkyl, —(CH2)n-aryl, hydroxy, halogen, lower alkoxy, morpholinyl, amino, lower alkylamino or —C(O)NR′2, and wherein R′ is lower alkyl or hydrogen, or is phenyl, optionally substituted by one or two substituents being halogen, lower alkyl, lower alkoxy, amino, di-lower alkyl amino, CF3, —OCF3, —NHC(O)lower alkyl, cyano, —C(O)-lower alkyl, —C(O)O-lower alkyl, —S-lower alkyl, —S(O)2NH-phenyl, —S(O)2-methylpiperazinyl; or is —NR′R″, wherein R′ and R″ are independently from each other hydrogen, —(CH2)nphenyl, which phenyl ring is optionally substituted by halogen or lower alkoxy, —CH(lower alkyl)-phenyl, indan-1-yl, 1,2,3,4-tetrahydro-naphthalen, or cycloalkyl; or is —O-phenyl, which phenyl ring is optionally substituted by halogen, lower alkyl or lower alkoxy, —O-tetrahydronaphthalenyl or —O—CH2-6-methyl-pyridin-2-yl; or is -benzo[1,3]dioxolyl, -1H-indol-5-yl, naphthyl, benzofuran-2-yl, 1,3,4,9-tetrahydro-b-carbolin-2-yl, piperidin-1-yl, pyrrolidin-1-yl, piperazin-4-yl-methyl or morpholinyl; R5 is —NR2, wherein R may be the same or different and is hydrogen, lower alkyl, phenyl, benzyl, —CO-lower alkyl, —CO-lower alkoxy, -lower alkenyl, —CO(CH2)n-phenyl or —COO(CH2)n-phenyl, wherein the phenyl ring is optionally substituted by CF3, lower alkoxy, halogen or lower alkyl, —CO(CH2)3-NHCO-lower alkoxy, —(CH2)n-phenyl, wherein the phenyl ring is optionally substituted by lower alkoxy, CF3 or halogen, or is 4,5-dihydro-1H-imidazol-2-yl-benzoic acid, 1,4,5,6-tetrahydro-pyrimidin-2-yl-benzoic acid or 4,5,6,7-tetrahydro-1H-[1,3]diazepin-2-yl-benzoic acid; n is 0-4 and their pharmaceutically acceptable salts

  该发明涉及以下式的化合物： 其中 R1是一个含有1至3个杂原子（N、O或S）的5或6元杂芳基团，该基团可以选择性地被一个或两个取代基取代，这些取代基可以是较低的烷基、—(CH2)nOH、卤素或较低的烷氧基，其中这些杂芳基团可以选择性地通过烷基或烯基基团与吡唑环连接，或者是苯基，可以选择性地被一个或两个取代基取代，这些取代基可以是较低的烷基、羟基较低烷基、卤素、羟基或较低的烷氧基，或者是—O(CH2)n、苯基、苯并呋喃基、吲哚基或苯并噻吩基，或者是—S-较低烷基； R2和R4彼此独立地是氢、氰基或—S(O)2-苯基； R3是氢、卤素或者是一个含有1至3个杂原子（N、O或S）的5或6元杂芳基团，该基团可以选择性地被一个或两个取代基取代，这些取代基可以是较低的烷基、—(CH2)n-芳基、羟基、卤素、较低的烷氧基、吗啉基、氨基、较低的烷基氨基或—C(O)NR′2，其中R′是较低的烷基或氢，或者是苯基，可以选择性地被一个或两个取代基取代，这些取代基可以是卤素、较低的烷基、较低的烷氧基、氨基、二较低烷基氨基、三氟甲基、—OCF3、—NHC(O)较低烷基、氰基、—C(O)-较低烷基、—C(O)O-较低烷基、—S-较低烷基、—S(O)2NH-苯基、—S(O)2-甲基哌嗪基；或者是—NR′R″，其中R′和R″彼此独立地是氢、—(CH2)n苯基，该苯环可以选择性地被卤素或较低的烷氧基取代，—CH(较低烷基)-苯基、茚基、1,2,3,4-四氢萘基，或环烷基；或者是—O-苯基，该苯环可以选择性地被卤素、较低的烷基或较低的烷氧基取代，—O-四氢萘基或—O—CH2-6-甲基吡啶-2-基；或者是-苯并[1,3]二噁咯基、-1H-吲哚-5-基、萘基、苯并呋喃-2-基、1,3,4,9-四氢-β-咔啉-2-基、哌啶-1-基、吡咯烷-1-基、哌嗪-4-基-甲基或吗啉基； R5是—NR2，其中R可以相同也可以不同，是氢、较低的烷基、苯基、苄基、—CO-较低烷基、—CO-较低烷氧基、-较低烯基、—CO(CH2)n-苯基或—COO(CH2)n-苯基，其中苯环可以选择性地被三氟甲基、较低的烷氧基、卤素或较低的烷基取代，—CO(CH2)3-NHCO-较低烷氧基、—(CH2)n-苯基，其中苯环可以选择性地被较低的烷氧基、三氟甲基或卤素取代，或者是4,5-二氢-1H-咪唑-2-基-苯甲酸、1,4,5,6-四氢-嘧啶-2-基-苯甲酸或4,5,6,7-四氢-1H-[1,3]二氮杂环己-2-基-苯甲酸； n为0-4 及其药学上可接受的盐
• Cyclic vinyl ether carbanions—II
  作者：Robert K. Boeckman、Kenneth J. Bruza

  DOI：10.1016/s0040-4020(01)93274-0

  日期：——

  Conditions for metalation of a variety of cyclic vinyl ethers and reaction of the resulting carbanions with electrophiles are described. Effects of the vinyl ether structure on the relative rates of metalation are discussed. Applications of this methodology to the construction of various types of carbonyl compounds are presented.

  描述了各种环状乙烯基醚的金属化条件以及所得碳负离子与亲电子试剂的反应条件。讨论了乙烯基醚结构对相对金属化速率的影响。介绍了该方法在各种类型羰基化合物的构建中的应用。
• Total Synthesis of (±)-Merrilactone A
  作者：Wei He、Jie Huang、Xiufeng Sun、Alison J. Frontier

  DOI：10.1021/ja0761986

  日期：2008.1.1

  The total synthesis of racemic merrilactone A (a neurotrophic agent) is described, featuring simultaneous and stereospecific creation of the C4 and C5 stereocenters via a notable silyloxyfuran Nazarov cyclization. Full details of the successful synthetic strategy are given, as well as several examples of the interesting reactivity of intermediates that were prepared and studied during the execution

  描述了外消旋 merrilactone A（一种神经营养剂）的全合成，其特点是通过显着的甲硅烷氧基呋喃 Nazarov 环化同时和立体定向地创建 C4 和 C5 立体中心。给出了成功合成策略的完整细节，以及在执行全合成过程中制备和研究的中间体的有趣反应性的几个例子。对路易斯酸催化的甲硅烷氧基呋喃 Nazarov 环化进行了详细研究，包括对底物范围和局限性的系统研究。此外，进行的实验表明路易斯酸性硅物质参与了纳扎罗夫环化。
• Lead Generation: Sowing the Seeds for Future Success
  作者：Konrad H. Bleicher、Matthias Nettekoven、Jens-Uwe Peters、René Wyler

  DOI：10.2533/000942904777677542

  日期：——

  Lead generation and the associated hit-to-lead process are key strategic elements in modern pharmaceutical research, and most companies have implemented this concept. Efficient lead generation is one of the main attempts to reduce the high attrition rates observed along the drug discovery process by focussing on the early developmental phases. The level of integration of the lead generation activities within the discovery organization, the flexibility in assessing and implementing new chemistries and new technologies, the high-quality standards set for the identification of the best possible chemical lead series will ultimately determine the future success in discovering new medicines.

  引导生成和相关的从击中到引导的过程是现代制药研究中的关键战略元素，大多数公司已经实施了这个概念。高效的引导生成是减少药物发现过程中观察到的高流失率的主要尝试之一，重点放在早期开发阶段。引导生成活动在发现组织内的整合程度、评估和实施新化学物质和新技术的灵活性、为了确定最佳化学引导系列的高质量标准最终将决定在发现新药物方面的未来成功。
• Synthesis and Comparative Antibacterial Activity of Verdamicin C2 and C2a. A New Oxidation of Primary Allylic Azides in Dihydro[2<i>H</i>]pyrans
  作者：Stephen Hanessian、Janek Szychowski、J. Pablo Maianti

  DOI：10.1021/ol802421d

  日期：2009.1.15

  A synthesis of verdamicin C2 and its congener C2a has been accomplished from sisomicin relying on a novel oxidative transformation of an allylic azide to the corresponding α,β-unsaturated aldehyde, and its stereocontrolled elaboration into the intended 5′ side chain of verdamicin C2 and C2a. In vitro antibacterial testing shows that both C6′ epimers in verdamicin C2 and C2a are equally active against

  威索霉素C2及其同类物C2a的合成已由sisomicin依赖于烯丙基叠氮化物向相应的α，β-不饱和醛的新型氧化转化以及其立体控制的精制成维达霉素C2和C2a的预期5'侧链。体外抗菌测试表明，维达霉素C2和C2a中的C6'差向异构体均对多种细菌菌株具有同等活性。2-取代的二氢[2 H ]吡喃的烯丙基伯叠氮化物，醚和酯与SeO 2的氧化直接导致相应的醛。